Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7622057 | 0.96 | MEN1 (0.46) | MEN1KMT2AL3MBTL1MAPTMAPK1 | |
| SCHEMBL11138560 | 0.94 | MEN1 (0.46) | MEN1KMT2AL3MBTL1MAPTMAPK1 | |
| SCHEMBL28454991 | 0.92 | MEN1 (0.44) | MEN1KMT2AL3MBTL1MAPTMAPK1 | |
| SCHEMBL11140940 | 0.87 | MEN1 (0.46) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11541470 | 0.87 | MEN1 (0.45) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL9306096 | 0.86 | MEN1 (0.47) | MEN1KMT2A | |
| SCHEMBL17787865 | 0.84 | MEN1 (0.40) | MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL9705177 | 0.83 | MEN1 (0.54) | MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL22070605 | 0.82 | MEN1 (0.49) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11537124 | 0.81 | MEN1 (0.50) | MEN1KMT2ATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767796-B2 | N4 chelator conjugates | GE HEALTHCARE LIMITED (GB) | 2010-08-03 | — | — | US | disclosed |
| US-7767796-B2 | N4 chelator conjugates | GE HEALTHCARE LIMITED (GB) | 2010-08-03 | — | — | US | disclosed |
| US-20080131368-A1 | N4 Chelator Conjugates | GE HEALTHCARE LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080131368-A1 | N4 Chelator Conjugates | GE HEALTHCARE LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131368-A1 | N4 Chelator Conjugates | TTK, PIGK, HUNK | MEN1 44/4885KMT2A 1001/4885L3MBTL1 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.